Figure 4
Effect of CED of cisplatin and immunotherapy on survival of GL261 tumour-bearing C57BL/6 mice. Kaplan-Meier survival curves of GL261-bearing mice receiving CED of cisplatin using a mini-osmotic pump/brain infusion kit at days 7–9, 0.01 μg/μl/h. (A) Addition of subcutaneous immunizations with 2 × 106 irradiated GL-wt cells at days 5, 19 and 33 (n = 48/n = 12 per group). Non-treated vs. GL-wt immunization (**p = 0.0024). Non-treated vs. cisplatin (**p = 0.0025). Non-treated vs. cisplatin + GL-wt immunization (**p = 0.0050), log rank test. (B) Addition of intraperitoneal immunizations with 2 × 106 irradiated GL-GM cells at days 5, 19 and 33 (n = 32/n = 9 for the treated groups and n = 5 for the non-treated group). Non-treated vs. GL-GM immunization (*p = 0.0117). Non-treated vs. cisplatin + GL-GM immunization (**p = 0.0033), log rank test. Survival was monitored for 100 days.
